Boston Scientific Adds Cathy Smith and Christophe Weber to Board

Got story updates? Submit your updates here. ›

Boston Scientific Corporation announced the election of Cathy Smith and Christophe Weber to its Board of Directors, effective February 18, 2026. Smith is the current Chief Financial Officer of Starbucks and has held CFO roles at several major companies. Weber is the retiring President and CEO of Takeda Pharmaceutical, bringing extensive global leadership experience in the pharmaceutical industry.

Why it matters

The addition of Smith and Weber to Boston Scientific's board brings valuable expertise in finance, corporate strategy, and global pharmaceutical operations that will help guide the medical device company through a period of growth and transformation. Their appointments follow the retirement of long-time board member John Sununu.

The details

Cathy Smith is a seasoned executive with deep expertise in finance, corporate strategy and operational excellence. She currently serves as Chief Financial Officer of Starbucks and has previously held CFO roles at Nordstrom, Bright Health, Target, Express Scripts and Walmart. Christophe Weber is the retiring President and CEO of Takeda Pharmaceutical, where he has led large-scale transformations focused on patient and customer-centricity. Prior to Takeda, he held roles of increasing responsibility at GlaxoSmithKline.

• Boston Scientific announced the board changes on February 23, 2026.
• Smith and Weber's appointments to the board were effective on February 18, 2026.
• Sununu will retire from the board at Boston Scientific's 2026 annual meeting.